Cancer - Wiki-Pi

Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide
EGFR and STAT3	epidermal growth factor receptor	signal transducer and activator of transcription 3 (acute-phase response factor)	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K/AKT activation PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by PDGF EGFR downregulation DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Axon guidance PIP3 activates AKT signaling L1CAM interactions EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signalling by NGF Signal transduction by L1 Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Signaling by FGFR SHC1 events in EGFR signaling Constitutive Signaling by EGFRvIII	Signaling by PDGF Signalling by NGF Signaling by FGFR in disease Cellular Senescence Interleukin-6 signaling Senescence-Associated Secretory Phenotype (SASP) Cytokine Signaling in Immune system NGF signalling via TRKA from the plasma membrane Signaling by SCF-KIT Signaling by Interleukins Transcriptional regulation of pluripotent stem cells Downstream signal transduction Signaling by FGFR1 mutants Signalling to STAT3 Signaling by FGFR mutants Signaling by FGFR1 fusion mutants POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation Signaling by Leptin Growth hormone receptor signaling	Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Flavopiridol Vandetanib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib
EGFR and SYK	epidermal growth factor receptor	spleen tyrosine kinase	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K/AKT activation PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by PDGF EGFR downregulation DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Axon guidance PIP3 activates AKT signaling L1CAM interactions EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signalling by NGF Signal transduction by L1 Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Signaling by FGFR SHC1 events in EGFR signaling Constitutive Signaling by EGFRvIII	Signaling by the B Cell Receptor (BCR) FCERI mediated MAPK activation Platelet Aggregation (Plug Formation) DAP12 signaling Regulation of signaling by CBL Role of phospholipids in phagocytosis Fcgamma receptor (FCGR) dependent phagocytosis FCGR activation Regulation of actin dynamics for phagocytic cup formation Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Innate Immune System DAP12 interactions Integrin alphaIIb beta3 signaling Cytokine Signaling in Immune system Role of LAT2/NTAL/LAB on calcium mobilization Signaling by Interleukins Fc epsilon receptor (FCERI) signaling GPVI-mediated activation cascade Interleukin-2 signaling FCERI mediated Ca+2 mobilization Platelet activation, signaling and aggregation Interleukin-3, 5 and GM-CSF signaling Adaptive Immune System	Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Flavopiridol Vandetanib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib	Staurosporine N-(2-hydroxy-1,1-dimethylethyl)-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indole-5-carboxamide 6-({5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)-2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one 2-{2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl}-N-[(1S)-2-hydroxy-1-methylethyl]-4-methyl-1,3-thiazole-5-carboxamide 2-{[(1R,2S)-2-aminocyclohexyl]amino}-4-[(3-methylphenyl)amino]pyrimidine-5-carboxamide Ellagic Acid
EGFR and ANKS1A	epidermal growth factor receptor	ankyrin repeat and sterile alpha motif domain containing 1A	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K/AKT activation PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by PDGF EGFR downregulation DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Axon guidance PIP3 activates AKT signaling L1CAM interactions EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signalling by NGF Signal transduction by L1 Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Signaling by FGFR SHC1 events in EGFR signaling Constitutive Signaling by EGFRvIII		Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Flavopiridol Vandetanib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib
EGFR and ADRM1	epidermal growth factor receptor	adhesion regulating molecule 1	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K/AKT activation PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by PDGF EGFR downregulation DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Axon guidance PIP3 activates AKT signaling L1CAM interactions EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signalling by NGF Signal transduction by L1 Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Signaling by FGFR SHC1 events in EGFR signaling Constitutive Signaling by EGFRvIII		Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Flavopiridol Vandetanib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib
EGFR and TGFA	epidermal growth factor receptor	transforming growth factor, alpha	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K/AKT activation PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by PDGF EGFR downregulation DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Axon guidance PIP3 activates AKT signaling L1CAM interactions EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signalling by NGF Signal transduction by L1 Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Signaling by FGFR SHC1 events in EGFR signaling Constitutive Signaling by EGFRvIII		Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Flavopiridol Vandetanib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib
EGFR and HGS	epidermal growth factor receptor	hepatocyte growth factor-regulated tyrosine kinase substrate	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K/AKT activation PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by PDGF EGFR downregulation DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Axon guidance PIP3 activates AKT signaling L1CAM interactions EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signalling by NGF Signal transduction by L1 Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Signaling by FGFR SHC1 events in EGFR signaling Constitutive Signaling by EGFRvIII	Signaling by EGFR EGFR downregulation Endosomal Sorting Complex Required For Transport (ESCRT) Signaling by EGFR in Cancer Signaling by Ligand-Responsive EGFR Variants in Cancer Signaling by Overexpressed Wild-Type EGFR in Cancer Signaling by EGFRvIII in Cancer	Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Flavopiridol Vandetanib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib
EGFR and PDGFRB	epidermal growth factor receptor	platelet-derived growth factor receptor, beta polypeptide	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K/AKT activation PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by PDGF EGFR downregulation DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Axon guidance PIP3 activates AKT signaling L1CAM interactions EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signalling by NGF Signal transduction by L1 Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Signaling by FGFR SHC1 events in EGFR signaling Constitutive Signaling by EGFRvIII	Signaling by the B Cell Receptor (BCR) Signaling by FGFR in disease PIP3 activates AKT signaling Signaling by EGFRvIII in Cancer Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation PI-3K cascade PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signaling by PDGF Signalling by NGF DAP12 interactions GAB1 signalosome Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Signaling by ERBB4 Role of LAT2/NTAL/LAB on calcium mobilization Constitutive PI3K/AKT Signaling in Cancer PI3K events in ERBB4 signaling Signaling by FGFR Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer PI3K/AKT Signaling in Cancer Adaptive Immune System	Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Flavopiridol Vandetanib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib	Becaplermin Sorafenib Imatinib Dasatinib Sunitinib Pazopanib Regorafenib
EGFR and UBB	epidermal growth factor receptor	ubiquitin B	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K/AKT activation PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by PDGF EGFR downregulation DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Axon guidance PIP3 activates AKT signaling L1CAM interactions EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signalling by NGF Signal transduction by L1 Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Signaling by FGFR SHC1 events in EGFR signaling Constitutive Signaling by EGFRvIII	Loss of Function of TGFBR2 in Cancer NF-kB is activated and signals survival Signaling by FGFR in disease Hedgehog 'off' state Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant Glucose metabolism Toll Like Receptor TLR1:TLR2 Cascade Signaling by NOTCH1 Signaling by NOTCH2 Toll Like Receptor 5 (TLR5) Cascade AXIN mutants destabilize the destruction complex, activating WNT signaling S33 mutants of beta-catenin aren't phosphorylated Stabilization of p53 Removal of licensing factors from origins Switching of origins to a post-replicative state Downregulation of ERBB2:ERBB3 signaling TGFBR2 MSI Frameshift Mutants in Cancer Signaling by NOTCH Endosomal Sorting Complex Required For Transport (ESCRT) Spry regulation of FGF signaling Signaling by NOTCH SCF(Skp2)-mediated degradation of p27/p21 deletions in the AMER1 gene destabilize the destruction complex Regulation of innate immune responses to cytosolic DNA Autodegradation of the E3 ubiquitin ligase COP1 Toll Like Receptor 3 (TLR3) Cascade Metabolism of carbohydrates CDK-mediated phosphorylation and removal of Cdc6 Cellular response to hypoxia Hedgehog ligand biogenesis p75NTR recruits signalling complexes Fanconi Anemia pathway Separation of Sister Chromatids HIV Infection APC truncation mutants have impaired AXIN binding Assembly of the pre-replicative complex Synthesis And Processing Of GAG, GAGPOL Polyproteins Activated TLR4 signalling S37 mutants of beta-catenin aren't phosphorylated p53-Dependent G1 DNA Damage Response regulation of FZD by ubiquitination Signaling by NOTCH1 PEST Domain Mutants in Cancer Signaling by NOTCH1 p53-Independent DNA Damage Response MyD88:Mal cascade initiated on plasma membrane Stimuli-sensing channels Membrane binding and targetting of GAG proteins p53-Independent G1/S DNA damage checkpoint G1/S DNA Damage Checkpoints Downregulation of ERBB4 signaling Vpu mediated degradation of CD4 Cell death signalling via NRAGE, NRIF and NADE ISG15 antiviral mechanism Interferon Signaling M/G1 Transition p75 NTR receptor-mediated signalling Signaling by FGFR Toll Like Receptor 10 (TLR10) Cascade Signaling by NOTCH1 in Cancer TCF dependent signaling in response to WNT SCF-beta-TrCP mediated degradation of Emi1 degradation of AXIN Degradation of GLI1 by the proteasome degradation of DVL Cell Cycle Checkpoints Signaling by WNT in cancer GLI3 is processed to GLI3R by the proteasome Regulation of Apoptosis Degradation of GLI2 by the proteasome Signaling by the B Cell Receptor (BCR) Vif-mediated degradation of APOBEC3G Signaling by NOTCH1 HD Domain Mutants in Cancer Constitutive Signaling by NOTCH1 HD Domain Mutants Downregulation of TGF-beta receptor signaling truncated APC mutants destabilize the destruction complex Cyclin E associated events during G1/S transition TGF-beta receptor signaling activates SMADs Regulation of PLK1 Activity at G2/M Transition FCERI mediated NF-kB activation Regulation of the Fanconi anemia pathway Generic Transcription Pathway G1/S Transition Toll Like Receptor 9 (TLR9) Cascade FBXW7 Mutants and NOTCH1 in Cancer IRAK1 recruits IKK complex Negative regulation of FGFR signaling truncations of AMER1 destabilize the destruction complex EGFR downregulation TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) IRAK2 mediated activation of TAK1 complex Processing-defective Hh variants abrogate ligand secretion Regulation of activated PAK-2p34 by proteasome mediated degradation Host Interactions of HIV factors phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex Signaling by ERBB4 Antiviral mechanism by IFN-stimulated genes Fc epsilon receptor (FCERI) signaling Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant Interleukin-3, 5 and GM-CSF signaling TAK1 activates NFkB by phosphorylation and activation of IKKs complex M Phase APC truncation mutants are not K63 polyubiquitinated Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon HIV Life Cycle Budding and maturation of HIV virion Hedgehog 'on' state Programmed Cell Death Class I MHC mediated antigen processing & presentation IKK complex recruitment mediated by RIP1 MAP kinase activation in TLR cascade Regulation of DNA replication Cytokine Signaling in Immune system Signaling by Overexpressed Wild-Type EGFR in Cancer MyD88-independent cascade Cell Cycle, Mitotic Signaling by TGF-beta Receptor Complex in Cancer Oxidative Stress Induced Senescence Activation of NF-kappaB in B cells Asymmetric localization of PCP proteins deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation TRAF6 mediated induction of TAK1 complex Negative regulators of RIG-I/MDA5 signaling misspliced GSK3beta mutants stabilize beta-catenin Hh ligand biogenesis disease SMAD2/3 MH2 Domain Mutants in Cancer T41 mutants of beta-catenin aren't phosphorylated Cellular Senescence Signaling by NOTCH1 HD Domain Mutants in Cancer Signaling by EGFRvIII in Cancer Assembly Of The HIV Virion Downstream signaling events of B Cell Receptor (BCR) Degradation of beta-catenin by the destruction complex NOD1/2 Signaling Pathway Glycogen storage diseases MyD88 dependent cascade initiated on endosome Mitotic G1-G1/S phases activated TAK1 mediates p38 MAPK activation Regulation of mRNA stability by proteins that bind AU-rich elements misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling TRIF-mediated TLR3/TLR4 signaling DNA Replication Pre-Initiation Senescence-Associated Secretory Phenotype (SASP) APC/C:Cdc20 mediated degradation of mitotic proteins TGFBR1 KD Mutants in Cancer S45 mutants of beta-catenin aren't phosphorylated Regulation of APC/C activators between G1/S and early anaphase Late Phase of HIV Life Cycle APC/C:Cdc20 mediated degradation of Cyclin B NOTCH2 Activation and Transmission of Signal to the Nucleus TCR signaling AMER1 mutants destabilize the destruction complex Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins Interleukin-1 signaling APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint PCP/CE pathway Mitotic G2-G2/M phases Adaptive Immune System APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 Regulation of Hypoxia-inducible Factor (HIF) by oxygen Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha Ubiquitin-dependent degradation of Cyclin D G2/M Transition TGFBR1 LBD Mutants in Cancer Oncogene Induced Senescence Autodegradation of Cdh1 by Cdh1:APC/C Ion channel transport p75NTR signals via NF-kB Regulation of signaling by CBL XAV939 inhibits tankyrase, stabilizing AXIN Disease TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation Signal Transduction Innate Immune System Synthesis of DNA Loss of Function of SMAD2/3 in Cancer TGFBR2 Kinase Domain Mutants in Cancer G1 Phase Signaling by Ligand-Responsive EGFR Variants in Cancer Loss of Function of TGFBR1 in Cancer Ubiquitin-dependent degradation of Cyclin D1 Activated NOTCH1 Transmits Signal to the Nucleus NOTCH1 Intracellular Domain Regulates Transcription Toll-Like Receptors Cascades Cyclin D associated events in G1 Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways Regulation of mitotic cell cycle Signaling by Hedgehog Association of licensing factors with the pre-replicative complex IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation Ubiquitin Mediated Degradation of Phosphorylated Cdc25A TCF7L2 mutants don't bind CTBP p53-Dependent G1/S DNA damage checkpoint Signaling by Wnt AUF1 (hnRNP D0) destabilizes mRNA Downregulation of SMAD2/3:SMAD4 transcriptional activity APC/C:Cdc20 mediated degradation of Securin SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription CDK-mediated phosphorylation and removal of Cdc6 Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer IRAK1 recruits IKK complex Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants RNF mutants show enhanced WNT signaling and proliferation Myoclonic epilepsy of Lafora Signaling by NOTCH1 in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer IRAK2 mediated activation of TAK1 complex Loss of Function of SMAD4 in Cancer AXIN missense mutants destabilize the destruction complex S Phase APC/C-mediated degradation of cell cycle proteins Toll Like Receptor 2 (TLR2) Cascade Signaling by ERBB2 Signaling by EGFR Signaling by Interleukins Glycogen synthesis NRIF signals cell death from the nucleus Toll Like Receptor 4 (TLR4) Cascade Signaling by EGFR in Cancer Signaling by NOTCH1 PEST Domain Mutants in Cancer SCF(Skp2)-mediated degradation of p27/p21 Cyclin A:Cdk2-associated events at S phase entry Constitutive Signaling by NOTCH1 PEST Domain Mutants Mitotic Metaphase and Anaphase Downstream TCR signaling Antigen processing: Ubiquitination & Proteasome degradation Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer Toll Like Receptor 7/8 (TLR7/8) Cascade Orc1 removal from chromatin Mitotic Anaphase deactivation of the beta-catenin transactivating complex Toll Like Receptor TLR6:TLR2 Cascade MyD88 cascade initiated on plasma membrane Activated NOTCH1 Transmits Signal to the Nucleus Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants FBXW7 Mutants and NOTCH1 in Cancer JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 Signalling by NGF Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer Cytosolic sensors of pathogen-associated DNA beta-catenin independent WNT signaling RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways Orc1 removal from chromatin Signaling by TGF-beta Receptor Complex CDT1 association with the CDC6:ORC:origin complex Antigen processing-Cross presentation ER-Phagosome pathway SMAD4 MH2 Domain Mutants in Cancer	Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Flavopiridol Vandetanib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib
EGFR and PIK3C2B	epidermal growth factor receptor	phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 beta	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K/AKT activation PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by PDGF EGFR downregulation DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Axon guidance PIP3 activates AKT signaling L1CAM interactions EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signalling by NGF Signal transduction by L1 Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Signaling by FGFR SHC1 events in EGFR signaling Constitutive Signaling by EGFRvIII	Synthesis of PIPs at the plasma membrane Metabolism of lipids and lipoproteins Phospholipid metabolism PI Metabolism	Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Flavopiridol Vandetanib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib
EGFR and PIK3R1	epidermal growth factor receptor	phosphoinositide-3-kinase, regulatory subunit 1 (alpha)	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K/AKT activation PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by PDGF EGFR downregulation DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Axon guidance PIP3 activates AKT signaling L1CAM interactions EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signalling by NGF Signal transduction by L1 Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Signaling by FGFR SHC1 events in EGFR signaling Constitutive Signaling by EGFRvIII	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Metabolism of lipids and lipoproteins Signaling by FGFR in disease Signaling by EGFRvIII in Cancer Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Interleukin receptor SHC signaling PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by FGFR1 mutants Interleukin-7 signaling Role of phospholipids in phagocytosis Phospholipid metabolism Fcgamma receptor (FCGR) dependent phagocytosis PI3K Cascade Signaling by PDGF DAP12 interactions GAB1 signalosome G-protein beta:gamma signalling CD28 co-stimulation CD28 dependent PI3K/Akt signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling G alpha (q) signalling events Signaling by ERBB2 Signaling by EGFR GPCR downstream signaling Signaling by Interleukins TCR signaling Signaling by VEGF GP1b-IX-V activation signalling Downstream signal transduction Signaling by FGFR mutants Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer Nephrin interactions Interleukin-2 signaling PI3K/AKT Signaling in Cancer Platelet activation, signaling and aggregation Interleukin-3, 5 and GM-CSF signaling Adaptive Immune System G alpha (q) signalling events Downstream TCR signaling Costimulation by the CD28 family IRS-mediated signalling PIP3 activates AKT signaling IGF1R signaling cascade VEGFA-VEGFR2 Pathway Synthesis of PIPs at the plasma membrane IRS-related events triggered by IGF1R G beta:gamma signalling through PI3Kgamma PI3K events in ERBB2 signaling Regulation of signaling by CBL Downstream signaling of activated FGFR G alpha (12/13) signalling events Antigen activates B Cell Receptor (BCR) leading to generation of second messengers PI Metabolism Innate Immune System Signaling by Insulin receptor Signalling by NGF Insulin receptor signalling cascade Cytokine Signaling in Immune system Signaling by Ligand-Responsive EGFR Variants in Cancer IRS-related events NGF signalling via TRKA from the plasma membrane Tie2 Signaling Signaling by Overexpressed Wild-Type EGFR in Cancer Cell surface interactions at the vascular wall Signaling by FGFR IRS-mediated signalling Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) GPVI-mediated activation cascade Interleukin receptor SHC signaling Signaling by FGFR1 fusion mutants Constitutive Signaling by EGFRvIII PI3K Cascade	Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Flavopiridol Vandetanib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib	Isoproterenol (1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-[(METHYLOXY)METHYL]-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO[4,3,2-DE]INDENO[4,5-H][2]BENZOPYRAN-11-YL ACETATE
EGFR and PIK3R2	epidermal growth factor receptor	phosphoinositide-3-kinase, regulatory subunit 2 (beta)	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K/AKT activation PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by PDGF EGFR downregulation DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Axon guidance PIP3 activates AKT signaling L1CAM interactions EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signalling by NGF Signal transduction by L1 Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Signaling by FGFR SHC1 events in EGFR signaling Constitutive Signaling by EGFRvIII	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Metabolism of lipids and lipoproteins Signaling by FGFR in disease Signaling by EGFRvIII in Cancer Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation Interleukin receptor SHC signaling PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Interleukin-7 signaling Role of phospholipids in phagocytosis Phospholipid metabolism Fcgamma receptor (FCGR) dependent phagocytosis PI3K Cascade Signaling by PDGF DAP12 interactions GAB1 signalosome G-protein beta:gamma signalling CD28 co-stimulation CD28 dependent PI3K/Akt signaling Signaling by ERBB4 Role of LAT2/NTAL/LAB on calcium mobilization Constitutive PI3K/AKT Signaling in Cancer PI3K events in ERBB4 signaling Signaling by ERBB2 G alpha (q) signalling events Signaling by EGFR GPCR downstream signaling Signaling by Interleukins TCR signaling Signaling by VEGF Signaling by Rho GTPases Downstream signal transduction Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer Nephrin interactions Interleukin-2 signaling PI3K/AKT Signaling in Cancer Platelet activation, signaling and aggregation Interleukin-3, 5 and GM-CSF signaling Adaptive Immune System G alpha (q) signalling events Downstream TCR signaling Costimulation by the CD28 family IRS-mediated signalling PIP3 activates AKT signaling IGF1R signaling cascade VEGFA-VEGFR2 Pathway Rho GTPase cycle Synthesis of PIPs at the plasma membrane IRS-related events triggered by IGF1R G beta:gamma signalling through PI3Kgamma PI3K events in ERBB2 signaling Regulation of signaling by CBL Downstream signaling of activated FGFR G alpha (12/13) signalling events PI Metabolism Innate Immune System Signaling by Insulin receptor Signalling by NGF Insulin receptor signalling cascade IRS-related events Cytokine Signaling in Immune system Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Tie2 Signaling Signaling by Overexpressed Wild-Type EGFR in Cancer Cell surface interactions at the vascular wall Signaling by FGFR IRS-mediated signalling Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) GPVI-mediated activation cascade Interleukin receptor SHC signaling PI3K Cascade	Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Flavopiridol Vandetanib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib
EGFR and PLCG1	epidermal growth factor receptor	phospholipase C, gamma 1	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K/AKT activation PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by PDGF EGFR downregulation DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Axon guidance PIP3 activates AKT signaling L1CAM interactions EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signalling by NGF Signal transduction by L1 Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Signaling by FGFR SHC1 events in EGFR signaling Constitutive Signaling by EGFRvIII	Signaling by the B Cell Receptor (BCR) Phospholipase C-mediated cascade Signaling by FGFR in disease FCERI mediated MAPK activation Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling DAP12 signaling Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Synthesis of IP3 and IP4 in the cytosol Signaling by FGFR1 mutants Role of phospholipids in phagocytosis Fcgamma receptor (FCGR) dependent phagocytosis Signaling by PDGF DAP12 interactions Inositol phosphate metabolism Antiviral mechanism by IFN-stimulated genes EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR TCR signaling Signaling by VEGF Downstream signal transduction Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer Signaling by FGFR mutants Frs2-mediated activation Adaptive Immune System Signalling to ERKs Prolonged ERK activation events Axon guidance DAG and IP3 signaling VEGFA-VEGFR2 Pathway VEGFR2 mediated cell proliferation Downstream signaling of activated FGFR Netrin-1 signaling Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Innate Immune System Signalling by NGF Generation of second messenger molecules ISG15 antiviral mechanism Interferon Signaling Cytokine Signaling in Immune system Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Signaling by FGFR PECAM1 interactions Cell surface interactions at the vascular wall Role of second messengers in netrin-1 signaling PLC-gamma1 signalling FCERI mediated Ca+2 mobilization Constitutive Signaling by EGFRvIII Signaling by FGFR1 fusion mutants	Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Flavopiridol Vandetanib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib
EGFR and SMURF2	epidermal growth factor receptor	SMAD specific E3 ubiquitin protein ligase 2	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K/AKT activation PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by PDGF EGFR downregulation DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Axon guidance PIP3 activates AKT signaling L1CAM interactions EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signalling by NGF Signal transduction by L1 Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Signaling by FGFR SHC1 events in EGFR signaling Constitutive Signaling by EGFRvIII	Loss of Function of TGFBR2 in Cancer Antigen processing: Ubiquitination & Proteasome degradation Downregulation of TGF-beta receptor signaling SMAD2/3 MH2 Domain Mutants in Cancer TGF-beta receptor signaling activates SMADs Signaling by Wnt Downregulation of SMAD2/3:SMAD4 transcriptional activity TGFBR1 LBD Mutants in Cancer Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer Signaling by BMP Generic Transcription Pathway RNF mutants show enhanced WNT signaling and proliferation Hedgehog 'on' state XAV939 inhibits tankyrase, stabilizing AXIN Class I MHC mediated antigen processing & presentation TGFBR2 MSI Frameshift Mutants in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Loss of Function of SMAD2/3 in Cancer TGFBR2 Kinase Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer TGFBR1 KD Mutants in Cancer Loss of Function of TGFBR1 in Cancer beta-catenin independent WNT signaling Signaling by TGF-beta Receptor Complex Signaling by TGF-beta Receptor Complex in Cancer TCF dependent signaling in response to WNT Asymmetric localization of PCP proteins Signaling by Hedgehog degradation of AXIN Signaling by WNT in cancer PCP/CE pathway SMAD4 MH2 Domain Mutants in Cancer Adaptive Immune System	Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Flavopiridol Vandetanib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib
EGFR and VAV1	epidermal growth factor receptor	vav 1 guanine nucleotide exchange factor	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K/AKT activation PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by PDGF EGFR downregulation DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Axon guidance PIP3 activates AKT signaling L1CAM interactions EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signalling by NGF Signal transduction by L1 Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Signaling by FGFR SHC1 events in EGFR signaling Constitutive Signaling by EGFRvIII	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease FCERI mediated MAPK activation Signaling by EGFRvIII in Cancer Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) PI3K/AKT activation PI-3K cascade Fcgamma receptor (FCGR) dependent phagocytosis Regulation of actin dynamics for phagocytic cup formation Signaling by PDGF DAP12 interactions GAB1 signalosome CD28 co-stimulation Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling Signaling by ERBB2 Signaling by EGFR GPCR downstream signaling Signaling by Interleukins Signaling by VEGF Signaling by Rho GTPases Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Platelet activation, signaling and aggregation Interleukin-3, 5 and GM-CSF signaling Adaptive Immune System Costimulation by the CD28 family PIP3 activates AKT signaling VEGFA-VEGFR2 Pathway Rho GTPase cycle PI3K events in ERBB2 signaling Downstream signaling of activated FGFR VEGFR2 mediated vascular permeability Regulation of signaling by CBL G alpha (12/13) signalling events Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Innate Immune System Signalling by NGF Cell death signalling via NRAGE, NRIF and NADE Cytokine Signaling in Immune system Signaling by Ligand-Responsive EGFR Variants in Cancer p75 NTR receptor-mediated signalling NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer CD28 dependent Vav1 pathway Signaling by FGFR NRAGE signals death through JNK GPVI-mediated activation cascade FCERI mediated Ca+2 mobilization	Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Flavopiridol Vandetanib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib
EGFR and TNC	epidermal growth factor receptor	tenascin C	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K/AKT activation PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by PDGF EGFR downregulation DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Axon guidance PIP3 activates AKT signaling L1CAM interactions EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signalling by NGF Signal transduction by L1 Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Signaling by FGFR SHC1 events in EGFR signaling Constitutive Signaling by EGFRvIII	Syndecan interactions ECM proteoglycans Integrin cell surface interactions Non-integrin membrane-ECM interactions	Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Flavopiridol Vandetanib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib
EGFR and YWHAZ	epidermal growth factor receptor	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K/AKT activation PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by PDGF EGFR downregulation DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Axon guidance PIP3 activates AKT signaling L1CAM interactions EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signalling by NGF Signal transduction by L1 Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Signaling by FGFR SHC1 events in EGFR signaling Constitutive Signaling by EGFRvIII	Translocation of GLUT4 to the plasma membrane Activation of BH3-only proteins Signaling by Wnt deactivation of the beta-catenin transactivating complex Rap1 signalling RNF mutants show enhanced WNT signaling and proliferation Programmed Cell Death XAV939 inhibits tankyrase, stabilizing AXIN Intrinsic Pathway for Apoptosis Regulation of mRNA stability by proteins that bind AU-rich elements misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Cytokine Signaling in Immune system Activation of BAD and translocation to mitochondria Signaling by Interleukins TCF dependent signaling in response to WNT KSRP destabilizes mRNA GP1b-IX-V activation signalling Signaling by WNT in cancer Platelet activation, signaling and aggregation Interleukin-3, 5 and GM-CSF signaling Adaptive Immune System	Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Flavopiridol Vandetanib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib
EGFR and PKIA	epidermal growth factor receptor	protein kinase (cAMP-dependent, catalytic) inhibitor alpha	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K/AKT activation PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by PDGF EGFR downregulation DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Axon guidance PIP3 activates AKT signaling L1CAM interactions EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signalling by NGF Signal transduction by L1 Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Signaling by FGFR SHC1 events in EGFR signaling Constitutive Signaling by EGFRvIII		Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Flavopiridol Vandetanib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib
EGFR and PRKAR1A	epidermal growth factor receptor	protein kinase, cAMP-dependent, regulatory, type I, alpha	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K/AKT activation PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by PDGF EGFR downregulation DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Axon guidance PIP3 activates AKT signaling L1CAM interactions EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signalling by NGF Signal transduction by L1 Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Signaling by FGFR SHC1 events in EGFR signaling Constitutive Signaling by EGFRvIII	Signaling by GPCR Ca-dependent events CaM pathway Glucagon-like Peptide-1 (GLP1) regulates insulin secretion Hedgehog 'off' state Integration of energy metabolism Phospholipase C-mediated cascade Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling DAG and IP3 signaling CaM pathway DAP12 signaling Downstream signaling of activated FGFR DARPP-32 events Glucagon signaling in metabolic regulation Innate Immune System Signaling by PDGF PKA activation in glucagon signalling Calmodulin induced events Signalling by NGF DAP12 interactions PKA-mediated phosphorylation of CREB PLC beta mediated events Vasopressin regulates renal water homeostasis via Aquaporins Opioid Signalling Regulation of insulin secretion Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane G-protein mediated events PKA activation Factors involved in megakaryocyte development and platelet production Signaling by Overexpressed Wild-Type EGFR in Cancer Aquaporin-mediated transport Signaling by FGFR EGFR interacts with phospholipase C-gamma Signaling by ERBB2 PKA-mediated phosphorylation of CREB Signaling by EGFR Downstream signal transduction Calmodulin induced events Signaling by Hedgehog PLC-gamma1 signalling Signaling by EGFR in Cancer PKA activation	Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Flavopiridol Vandetanib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib
EGFR and PRKAR1B	epidermal growth factor receptor	protein kinase, cAMP-dependent, regulatory, type I, beta	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K/AKT activation PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by PDGF EGFR downregulation DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Axon guidance PIP3 activates AKT signaling L1CAM interactions EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signalling by NGF Signal transduction by L1 Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Signaling by FGFR SHC1 events in EGFR signaling Constitutive Signaling by EGFRvIII	Signaling by GPCR Ca-dependent events CaM pathway Glucagon-like Peptide-1 (GLP1) regulates insulin secretion Hedgehog 'off' state Integration of energy metabolism Phospholipase C-mediated cascade Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling DAG and IP3 signaling CaM pathway DAP12 signaling Downstream signaling of activated FGFR DARPP-32 events Glucagon signaling in metabolic regulation Innate Immune System Signaling by PDGF PKA activation in glucagon signalling Calmodulin induced events Signalling by NGF DAP12 interactions PKA-mediated phosphorylation of CREB PLC beta mediated events Vasopressin regulates renal water homeostasis via Aquaporins Opioid Signalling Regulation of insulin secretion Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane G-protein mediated events PKA activation Factors involved in megakaryocyte development and platelet production Signaling by Overexpressed Wild-Type EGFR in Cancer Aquaporin-mediated transport Signaling by FGFR EGFR interacts with phospholipase C-gamma Signaling by ERBB2 PKA-mediated phosphorylation of CREB Signaling by EGFR Downstream signal transduction Calmodulin induced events Signaling by Hedgehog PLC-gamma1 signalling Signaling by EGFR in Cancer PKA activation	Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Flavopiridol Vandetanib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib
EGFR and PRKCA	epidermal growth factor receptor	protein kinase C, alpha	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K/AKT activation PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by PDGF EGFR downregulation DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Axon guidance PIP3 activates AKT signaling L1CAM interactions EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signalling by NGF Signal transduction by L1 Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Signaling by FGFR SHC1 events in EGFR signaling Constitutive Signaling by EGFRvIII	Ca-dependent events Signaling by GPCR CaM pathway Signaling by FGFR in disease Phospholipase C-mediated cascade Integration of energy metabolism Mitotic Prophase Signaling by Wnt Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Regulation of KIT signaling Gastrin-CREB signalling pathway via PKC and MAPK Response to elevated platelet cytosolic Ca2+ G alpha (z) signalling events Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell Signaling by PDGF Calmodulin induced events DAP12 interactions Regulation of mRNA stability by proteins that bind AU-rich elements Opioid Signalling Diseases associated with visual transduction EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Syndecan interactions GPCR downstream signaling Signaling by VEGF Calmodulin induced events Downstream signal transduction WNT5A-dependent internalization of FZD4 Signaling by EGFR in Cancer Platelet activation, signaling and aggregation PCP/CE pathway Transmission across Chemical Synapses Trafficking of GluR2-containing AMPA receptors Nuclear Envelope Breakdown HuR stabilizes mRNA DAG and IP3 signaling M Phase VEGFA-VEGFR2 Pathway CaM pathway Inactivation, recovery and regulation of the phototransduction cascade EGFR Transactivation by Gastrin VEGFR2 mediated cell proliferation Downstream signaling of activated FGFR The phototransduction cascade Disinhibition of SNARE formation Innate Immune System Signalling by NGF PLC beta mediated events Regulation of insulin secretion Depolymerisation of the Nuclear Lamina Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane G-protein mediated events Non-integrin membrane-ECM interactions Signaling by Overexpressed Wild-Type EGFR in Cancer Trafficking of AMPA receptors Cell Cycle, Mitotic Signaling by FGFR beta-catenin independent WNT signaling Acetylcholine regulates insulin secretion Visual phototransduction Ca2+ pathway PLC-gamma1 signalling Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity	Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Flavopiridol Vandetanib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib	Phosphatidylserine Vitamin E Ingenol Mebutate Ellagic Acid

Search Results for: Cancer